Home
Home

Rituxan

Roche Pays $20M To Settle Whistleblower Lawsuit

Roche Pays $20M To Settle Whistleblower Lawsuit
Pharmalot

Biogen to take $50M hit from lymphoma drug dispute

Biogen to take $50M hit from lymphoma drug dispute
Bizjournals.com

FDA approves Genentech vasculitis treatment

FDA approves Genentech vasculitis treatment
Bizjournals.com

News

FDA Approves Rituxan for First-Line Maintenance Use in Follicular Lymphoma
BusinessWire

News

Biosimilars: Empty Threats?
InVivo

News

Novartis plans trial of equivalent to Roche drug
Marketwatch

News

Spectrum Pharma Jumps in With the Big Dogs
Motley Fool

News

Genentech: positive results from cancer drug study
Yahoo/AP

News

Phase III Study Showed Rituxan® for Initial Use Followed by Continued Use Delayed the Need for Additional Therapy in People with Asymptomatic Follicular Lymphoma, a Common Type of Blood Cancer
Yahoo/BusinessWire

News

EMA: Few pharmas expected to tackle biosimilar antibodies
Fierce Biotech
»